Enterprise Dose Monitoring

Request for Information (RFI) of Small Business capability for the Defense Health Agency (DHA) Enterprise Dose Monitoring System

1.0 DISCLAIMER: This is NOT a Request for Proposal (RFP) nor a Request for Quotation (RFQ). It is strictly a Request for Information (RFI) to determine if Small Business is capable of meeting the Government’s requirement. Only Small Business responses will be considered. This RFI should not be construed as a formal solicitation nor an obligation on the part of the Government to acquire any products or services. Neither unsolicited proposals nor any other kinds of offers will be considered in response to this RFI, and no contract will be awarded pursuant to this announcement. The information requested by this RFI will be used within the DHA to facilitate decision making and will not be disclosed outside of the DHA. Any information provided to the Government is strictly voluntary and will be provided at no cost to the Government.

2.0 SUBJECT: The Medical Research and Development Contracting Division 2, Defense Health Agency Contracting Activity (DHACA), is seeking information in the form of capabilities statements and availability. This RFI is for fact-finding and planning purposes only. The information will be used in conducting market research to identify qualified, experienced, and interested potential Small Business sources in support of the Government’s requirements outlined in Attachment 1, which are subject to change prior to a formal solicitation release. The Government reserves the right to decide whether a small business set-aside is appropriate based on responses to this notice. Contractors are encouraged to inform the Government of any barriers that would prohibit them from competing. Contact with Government personnel, other than those specified in the RFI, by potential offerors or their employees regarding this requirement is not permitted.

3.0 BACKGROUND: The DHA relies on timely, accurate, and compliant dose monitoring to support patient safety, clinical decision making, and mission readiness. Clinicians and medical physicists manage high volumes of dose data, often under critical conditions like emergency care, trauma, and diagnostic imaging. As the DHA moves toward standardization, the goal is to consolidate dose monitoring into a single enterprise system with real-time analytics, integrated data workflows, and robust security to drive efficiency and compliance:

• Highly accurate, specialty-tuned dose monitoring calibrated for specialized imaging modalities.
• Rapid, uninterrupted data capture workflows that drive productivity and reduce report turnaround times.
• Secure handling of dose data containing Protected Health Information (PHI), ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA) and other regulatory requirements.
• Reliable operation in bandwidth-constrained environments, including Outside the Continental United States (OCONUS) Military Treatment Facilities (MTFs) and remote telemedicine missions.
• Seamless integration with existing Picture Archiving and Communication Systems (PACS), Radiology Information System (RIS), and Electronic Health Record (EHR) systems for unified dose tracking and reporting.

An enterprise dose monitoring system must provide consistent data formatting, customizable templates, macro support, and the ability to capture specialized metrics across imaging modalities such as neuroradiology, Musculoskeletal (MSK), and Nuclear Medicine. The DHA seeks commercial solutions that can scale these capabilities while meeting cybersecurity, interoperability, and operational requirements in the Department of War (DoW) environment.

4.0 SCOPE: The Medical Research and Development Contracting Division 2, DHACA, is issuing an RFI to identify Small Businesses capable of meeting the Government’s requirement.  The Government requests a Capability Statement outlining a proposed solution that includes the following:

1. Enterprise dose monitoring solution that meets the DHA requirements for real-time dose tracking, clinical decision support, and regulatory compliance.
2. Integrate with PACS, Military Health System (MHS) GENESIS/Cerner, and other DHA clinical systems.
3. Comply with DoW cybersecurity, identity, and Zero-Trust policies.
4. Support all Radiologists across CONUS and OCONUS sites.
5. Operate effectively in variable network conditions.
6. Provide a central system that has central administration, reporting, and access governance.
7. A draft implementation plan outlining the potential solution to the Government’s requirement. The plan should highlight the key deliverables, timelines, and expectations of each party responsible for delivery, configuration, and final acceptance of the systems, and include the total number of project managers and implementation team(s) involved. Detailed steps and task owners for implementation as well as expected completion time for each task are requested.  Please also provide timelines for production and implementation. Implementation is defined utilizing a “Go-live” date accomplished by full clinical usage of the system with fulfillment of migration requirements with no reliance on the legacy system. In addition, the Government requests feedback regarding potential risks and mitigation strategies.

Vendors may also propose alternative or innovative approaches.

In your capability statement, address how you would deliver/implement the specific tasks outlined in Attachment 1.

Task Areas:

1.0 System Architecture & Availability

2.0 Workstation, PACS, and Operating System (OS) Integration

3.0 Enterprise Workload, Templates, & Reporting

4.0 Hardware & Peripheral Requirements

5.0 Clinical Workflow & Critical Results

6.0 DoW System Integration

7.0 DoW Cybersecurity & Risk Management Framework (RMF) Requirements

5.0 SMALL BUSINESS SET ASIDE: The Government has not determined the set-aside capability at this time. The Government will use the RFI results in analyzing small businesses’ capacity to perform this requirement and make its decision.

6.0 RESPONSE INSTRUCTIONS: If your firm can provide the requirements described in Attachment 1, please provide a Capability Statement to the Medical Research and Development Contracting Division 2, DHACA, Ms. Jennifer Sikes, jennifer.m.sikes2.civ@health.mil. A vendor responding to this RFI with generic material only, such as brochures, advertisements, or other generic material, is highly discouraged.

The following information is requested:

(a) Capability Statement

(b) company Cage Code, Unique Entity Identifier (UEI), company name, address, point of contact and their telephone number, email address and company structure (Corporation, LLC, partnership, joint venture, etc.). Companies must be registered in the System for Award Management (SAM, at www.sam.gov) to be considered as potential sources.

(c) Small Business Designation status such as (8(a), HUBZone, Service-Disabled Veteran Owned Small Business (SDVOSB), women-owned, etc.). Maximum participation by small business, veteran-owned small business, service-disabled veteran-owned small business, HUBZone small business, small-disadvantaged business, and women-owned small business concerns is encouraged.

(d) indicate which North American Industry Classification System (NAICS) code(s) your company usually performs under for Government contracts.

(e) Information pertaining to the following:

1. Does your company participate in any contracting vehicles such as Government-wide Acquisition Contracts (GWACS), Multiple-Award Contracts (MAC) or Indefinite Delivery, Indefinite Quantity contracts (IDIQ)? If so, please provide detailed information regarding which, contract numbers and relevant categories.

1. Does your company have a Federal Supply Schedule (FSS)? If so, please provide detailed information regarding which, schedule numbers and relevant categories.

Submission: Please submit an electronic copy of the capabilities statement in a “.pdf” file type and via email to the Medical Research and Development Contracting Division 2, DHACA, Ms. Jennifer Sikes at jennifer.m.sikes2.civ@health.mil. The subject line of the email should be: “Enterprise Dose Monitoring – RFI Response.”

Due date: RFI response submission are due no later than.

Page Limit: RFI responses shall be limited to 20 pages, not including cover and administrative pages, and written using a 12-point font size. Beyond the 20-page limit, the Government may only review examples of media and graphic design.

Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Parties may begin submitting responses to this RFI immediately. If the information provided contains propriety information, such information must be clearly identified with appropriate disclaimers.

THIS IS NOT A SOLICITATION ANNOUNCEMENT OR REQUEST FOR PROPOSALS, AND NO CONTRACT WILL BE AWARDED FROM THIS ANNOUNCEMENT.